Abstract Increasing evidence suggests that renal inflammation contributes to the pathogenesis and progression of diabetic kidney disease (DKD) and that anti-inflammatory therapies might have renoprotective effects in DKD
More than 80 peptide drugs are already approved worldwide, including insulin, GLP-1 receptor agonists for diabetes and obesity, vasopressin analogues for shock, and linaclotide for irritable bowel syndrome
Kaestner L, Bogdanova A, Egee S
Si un proveedor no puede proporcionar este documento, eso es una seal clara de que su cadena de trazabilidad es deficiente
A good interpretation should leave you with a plan, not just a label
Biochem J 334 (Pt 1), 261267 (1998)